Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

39.45 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 39.45
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 39.45
Today's Range 39.45 - 39.45
52wk Range 29.20 - 42.43
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
NFLX is among four stocks on the list that's actionable now. 
Via Investor's Business Daily
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in households, marking a global first for an antiviral. 
Via Benzinga

Performance

YTD
+8.53%
+8.53%
1 Month
-5.42%
-5.42%
3 Month
+10.47%
+10.47%
6 Month
+26.08%
+26.08%
1 Year
+15.49%
+15.49%

More News

Read More
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
From Genentech
Via Business Wire
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Via The Motley Fool
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
Via Benzinga
Exposures Product Safety
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
From Genentech
Via Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
Via Investor's Business Daily
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Via The Motley Fool
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
From Genentech
Via Business Wire
Why Roche Holdings Stock Withered on Wednesday
Via The Motley Fool
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Via Benzinga
Exposures COVID-19
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
Via Investor's Business Daily
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Via Benzinga
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter
Via Investor's Business Daily
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Via The Motley Fool
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Via Benzinga
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Via Benzinga
Exposures Product Safety
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
Via The Motley Fool
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.